Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/9/2023 | $53.00 → $42.00 | Outperform → Neutral | Wedbush |
| 9/8/2022 | $55.00 | Buy | Guggenheim |
| 3/28/2022 | $75.00 | Outperform | Wedbush |
| 11/5/2021 | $79.00 → $80.00 | Buy | HC Wainwright & Co. |
| 9/16/2021 | $82.00 → $84.00 | Outperform | Wedbush |
| 7/21/2021 | $73.00 → $82.00 | Outperform | Wedbush |
4 - ALBIREO PHARMA, INC. (0001322505) (Issuer)
4 - ALBIREO PHARMA, INC. (0001322505) (Issuer)
4 - ALBIREO PHARMA, INC. (0001322505) (Issuer)
– Dr. Craig Hopkinson, currently EVP of Research & Development and Chief Medical Officer at Alkermes, brings strong global orphan drug development expertise – Dr. Paul Streck, former Chief Medical Officer at Arena Pharmaceuticals, brings significant global drug development and commercialization expertise – Two appointments strengthen Company's ability to scale up global drug development and grow the portfolio BOSTON, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced the appointments of two scientific leaders, Drs. Paul Streck and Craig Hopki
– Habib Dable, Former President and CEO of Acceleron Pharma, and Susan Alesina, Vice President, National Business Development and Alliances at Boston Children's Hospital, bring significant global drug development, financial and commercial operations expertise to Albireo BOSTON, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced the appointments of Habib Dable and Susan Alesina to its Board of Directors — two experienced, strategic leaders with vast pharmaceutical and biotech expertise in business development, operations and commercialization. T
BASEL, Switzerland, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of Michael Gutch, Ph.D., as Chief Financial Officer. Dr. Gutch has extensive experience in the healthcare and pharmaceutical industries and venture capital investment. He served as Executive Director of Corporate Development and Head of Equities at AstraZeneca and was most recently Chief Business Officer and Chief Financial Officer at Entasis Therapeutics, an AstraZeneca spin-off, where he was involved in the company's private financing rounds, its NASDAQ listing in 2018 and in the strategic partneri
Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023 Extension allows for the satisfaction of the HSR Act related condition as outlined in the Merger AgreementAlbireo stockholders are encouraged to tender their shares to the offer today PARIS, FRANCE, 22 February 2023 – Ipsen S.A. ((Euronext: IPN, OTC:IPSEY) today announced that Anemone Acquisition Corp. (Purchaser), its wholly owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock (the "Shares") of Albireo Pharma, Inc. (NASDAQ:ALBO) (Albireo) at a price of $42.00 per share, net to the holder
Bylvay (odevixibat) granted Priority Review by U.S. FDAASSERT study demonstrated efficacy of Bylvay in pruritus, bile acids and sleep with a low drug-related diarrhea rate in Alagille patientsApproval in second indication would more than double Bylvay market opportunity BOSTON, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's supplemental New Drug Application (sNDA) and issued a Prescription Drug User Fee Act (PDUFA) action date of June 15, 2023 for a second Bylvay (odevixi
Transaction focused on Bylvay® (odevixibat), the first-approved treatment in progressive familial intrahepatic cholestasis in U.S. and E.U., with potential in other rare diseases Acquisition aligned with Ipsen's long-term strategy for expanding the scope of its Rare Disease portfolio and pipeline Ipsen to commence cash tender offer to acquire all issued and outstanding shares of Albireo for $42.00 per share plus a contingent value right (CVR) of $10.00 per share related to the U.S. FDA approval of Bylvay in biliary atresia Regulatory News: Ipsen (OTC:IPSEY) and Albireo (NASDAQ:ALBO) today announced that they have entered into a definitive merger agreement under which Ipsen will acqu
SC 13G/A - ALBIREO PHARMA, INC. (0001322505) (Subject)
SC 13G/A - ALBIREO PHARMA, INC. (0001322505) (Subject)
SC 13G - ALBIREO PHARMA, INC. (0001322505) (Subject)
Submission status for ALBIREO PHARMA INC's drug BYLVAY (ORIG-1) with active ingredient ODEVIXIBAT has changed to 'Approval' on 07/20/2021. Application Category: NDA, Application Number: 215498, Application Classification: Type 1 - New Molecular Entity
15-12G - ALBIREO PHARMA, INC. (0001322505) (Filer)
EFFECT - ALBIREO PHARMA, INC. (0001322505) (Filer)
EFFECT - ALBIREO PHARMA, INC. (0001322505) (Filer)
Transaction focused on Bylvay® (odevixibat), the first-approved treatment in progressive familial intrahepatic cholestasis in U.S. and E.U., with potential in other rare diseases Acquisition aligned with Ipsen's long-term strategy for expanding the scope of its Rare Disease portfolio and pipeline Ipsen to commence cash tender offer to acquire all issued and outstanding shares of Albireo for $42.00 per share plus a contingent value right (CVR) of $10.00 per share related to the U.S. FDA approval of Bylvay in biliary atresia Regulatory News: Ipsen (OTC:IPSEY) and Albireo (NASDAQ:ALBO) today announced that they have entered into a definitive merger agreement under which Ipsen will acqu
Bylvay® (odevixibat) Q3 2022 PFIC net revenue of $7.5 million, September YTD 2022 $18.1 millionNew disease modification and native liver survival data with Bylvay in PFIC patients presented at AASLD Positive Bylvay Phase 3 ASSERT topline data in ALGS presented at AASLD; submissions on track Completed enrollment in BOLD study in biliary atresia, third Bylvay Phase 3 programCompany to host a conference call and webcast today at 4:30 p.m. ET BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a rare disease company developing novel bile acid modulators to treat rare pediatric and adult liver diseases, today provided a business update and reported financial results
BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 4:30 p.m. ET on November 8, 2022, to provide a business update and review the company's financial results for the quarter ended September 30, 2022. To access the live conference call by phone, dial 1-855-327-6837 (domestic) or 1-631-891-4304 (international), and provide the access code 10020423. A live audio webcast will be accessible from the Investors page at ir.albireopharma.com/. To ensure a timely connection to the webcast, it is recommended that partici
Wedbush downgraded Albireo Pharma from Outperform to Neutral and set a new price target of $42.00 from $53.00 previously
Guggenheim initiated coverage of Albireo Pharma with a rating of Buy and set a new price target of $55.00
Wedbush initiated coverage of Albireo Pharma with a rating of Outperform and set a new price target of $75.00
Albireo Pharma (NASDAQ:ALBO) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 0 5 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 4 0 0 3M Ago 0 0 0 0 0 These 5 analysts have an average price target of $43.2 versus the current price of Albireo Pharma at $44.29, implying downside. Below is a summary of how these 5 analysts rated Albireo Pharma over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock This current average represen
HC Wainwright & Co. analyst Ed Arce reiterates Albireo Pharma (NASDAQ:ALBO) with a Neutral and maintains $42 price target.